Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes a mismatch of scale between the company and the demand it is already serving. The key is: the company is already inside a large flow, with real business, and management explicitly draws the size contrast, treating it as a central fact. Let's examine the transcript. Management discusses several areas: ICP (liquid biopsy), Pathology services, IV-Cell, HemeScreen. They mention partnerships with Perkin Elmer, revenue projections, etc. Specifically, for ICP: "we estimate 2019 revenues between several hundreds to several million dollars resulting from the market penetration of ICP within current and future Perkin Elmer and Precipio customers with a potential of significant growth from there on in future years as we capture a substantial share of this plus $1 billion market." This is a projection for 2019, not current. They have a co-marketing agreement, but is there current business? They say "The co-marketing agreement recently announced is the first step in building a strong ongoing relationship." So it's recent, not yet generating revenue. They talk about "market penetration" as future. So this is prospective. For Pathology services: "our revenues from pathology services growing close to 50% from the previous quarter. With a substantial pipeline of new customers and strong conversion rates, we expect a continued rapid growth of this side of our business with revenues from pathology services alone exceeding $1 million per quarter by the middle of 2019." This is current growth, but they don't explicitly contrast the size of the market or the demand with the company's size. They mention "pipeline" and "conversion rates" but not a specific large flow they are already inside. They talk about "customers" but no explicit scale mismatch. For HemeScreen: "Since the launch of the test in our lab, only two weeks ago, we've already received numerous orders -- we've already run numerous orders received from physicians. We believe that given the market volume and revenue numbers of the current inferior test, that HemeScreen can generate revenues in excess of $1 million in 2019 and rapidly increase in the following years. This is not including potential licensing and other partnerships we're currently working on to capture this $100 million U.S.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.